Literature DB >> 22425664

Peritoneal washing cytology in patients with BRCA1 or BRCA2 mutations undergoing risk-reducing salpingo-oophorectomies: a 10-year experience and reappraisal of its clinical utility.

G Landon1, J Stewart, M Deavers, K Lu, N Sneige.   

Abstract

OBJECTIVE: To evaluate the utility of peritoneal washing cytology (PWC) for detecting occult primary peritoneal carcinoma in patients with BRCA1 or BRCA2 mutations, we reviewed PWCs obtained during risk-reducing salpingo-oophorectomy (RRSO) from 117 patients at our institution and correlated the results with surgical pathology findings.
METHODS: Records of 128 PWCs from 125 patients with BRCA1 or BRCA2 mutations undergoing RRSO at MD Anderson Cancer Center between 2000 and 2010 were obtained. Slides were available for review for 119 PWCs from 117 patients (2 patients had 2 PWCs each). Cytopathologists, blinded to the RRSO histopathologic diagnoses, categorized the PWCs as benign, atypical, suspicious for malignancy, or malignant. These results were correlated with the RRSO histopathologic diagnoses.
RESULTS: PWCs from 113 patients were benign. Of the remaining 4 patients, 2 had PWCs classified as atypical, 1 as suspicious for malignancy, and 1 as malignant. The corresponding RRSO histopathologic findings of the 2 atypical PWCs showed endosalpingiosis and cystadenofibroma in one case and showed no abnormalities in the other case. Both patients with suspicious or malignant PWCs, indicating the possibility of occult peritoneal carcinoma, had RRSO histopathologic diagnoses of endometriosis and endosalpingiosis. Nine patients had abnormal tubal or ovarian histologic findings, but all 9 of these patients had benign PWCs.
CONCLUSION: PWC has the potential to detect occult peritoneal carcinoma in patients with BRCA1 or BRCA2 mutations. The clinical significance of a positive PWC without abnormal RRSO histology remains unclear and will require long-term follow-up for determination.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22425664      PMCID: PMC3873851          DOI: 10.1016/j.ygyno.2012.03.009

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  37 in total

1.  Utility of peritoneal lavage cytology during laparoscopic salpingo-oophorectomy: a retrospective analysis.

Authors:  K Haldar; P Giamougiannis; R Crawford
Journal:  BJOG       Date:  2010-11-04       Impact factor: 6.531

2.  Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy.

Authors:  K H Lu; J E Garber; D W Cramer; W R Welch; J Niloff; D Schrag; R S Berkowitz; M G Muto
Journal:  J Clin Oncol       Date:  2000-07       Impact factor: 44.544

3.  Prophylactic salpingo-oophorectomy in a series of 89 women carrying a BRCA1 or a BRCA2 mutation.

Authors:  Fatima Laki; Youlia M Kirova; Pascale This; Corinne Plancher; Bernard Asselain; Xavier Sastre; Dominique Stoppa-Lyonnet; Remy Salmon
Journal:  Cancer       Date:  2007-05-01       Impact factor: 6.860

4.  Ovarian pathology in risk-reducing salpingo-oophorectomies from women with BRCA mutations, emphasizing the differential diagnosis of occult primary and metastatic carcinoma.

Authors:  Joseph T Rabban; Michael Barnes; Lee-May Chen; Catherine B Powell; Beth Crawford; Charles J Zaloudek
Journal:  Am J Surg Pathol       Date:  2009-08       Impact factor: 6.394

5.  Occult cancer of the fallopian tube in BRCA-1 germline mutation carriers at prophylactic oophorectomy: a case for recommending hysterectomy at surgical prophylaxis.

Authors:  P J Paley; E M Swisher; R L Garcia; S N Agoff; B E Greer; K L Peters; B A Goff
Journal:  Gynecol Oncol       Date:  2001-02       Impact factor: 5.482

6.  High rates of occult fallopian tube cancer diagnosed at prophylactic bilateral salpingo-oophorectomy.

Authors:  Jane E Hirst; Gregory B Gard; Kirsty McIllroy; David Nevell; Michael Field
Journal:  Int J Gynecol Cancer       Date:  2009-07       Impact factor: 3.437

Review 7.  Hereditary ovarian cancer--assessing risk and prevention strategies.

Authors:  James C Pavelka; Andrew J Li; Beth Y Karlan
Journal:  Obstet Gynecol Clin North Am       Date:  2007-12       Impact factor: 2.844

Review 8.  Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA2.

Authors:  Noah D Kauff; Richard R Barakat
Journal:  J Clin Oncol       Date:  2007-07-10       Impact factor: 44.544

9.  Candidate serous cancer precursors in fallopian tube epithelium of BRCA1/2 mutation carriers.

Authors:  Patricia A Shaw; Marjan Rouzbahman; Ellen S Pizer; Melania Pintilie; Heather Begley
Journal:  Mod Pathol       Date:  2009-06-19       Impact factor: 7.842

10.  Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Anglian Breast Cancer Study Group.

Authors: 
Journal:  Br J Cancer       Date:  2000-11       Impact factor: 7.640

View more
  5 in total

1.  Long term follow up of BRCA1 and BRCA2 mutation carriers with unsuspected neoplasia identified at risk reducing salpingo-oophorectomy.

Authors:  C B Powell; E M Swisher; I Cass; J McLennan; B Norquist; R L Garcia; J Lester; B Y Karlan; L Chen
Journal:  Gynecol Oncol       Date:  2013-02-04       Impact factor: 5.482

2.  Abdominopelvic washings: A comprehensive review.

Authors:  Erika F Rodriguez; Sara E Monaco; Walid Khalbuss; R Marshall Austin; Liron Pantanowitz
Journal:  Cytojournal       Date:  2013-04-24       Impact factor: 2.091

3.  Challenges in Managing Patients with Hereditary Cancer at Gynecological Services.

Authors:  Mako Ueda; Hiroshi Tsubamoto; Mina Kashima-Morii; Yoshitaka Torii; Mariko Kamihigashi; Yu Wakimoto; Nami Nakagomi; Tomoko Hashimoto-Tamaoki; Hideaki Sawai; Hiroaki Shibahara
Journal:  Obstet Gynecol Int       Date:  2019-05-27

Review 4.  Diagnostic Cytopathology of Peritoneal Washings.

Authors:  Rosemary E Zuna
Journal:  Cytojournal       Date:  2022-02-28       Impact factor: 2.345

Review 5.  The lack of clinical value of peritoneal washing cytology in high risk patients undergoing risk-reducing salpingo-oophorectomy: a retrospective study and review.

Authors:  F Blok; E M Roes; G J L H van Leenders; H J van Beekhuizen
Journal:  BMC Cancer       Date:  2016-01-14       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.